ReviewThe oncologist2013
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
Review in The oncologist, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 79 citations in OpenAlex.
- Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Combined cold atmospheric plasma and vemurafenib suppress MITF-P21 signaling and MMP-driven metastasis in cutaneous melanoma.Iranian journal of basic medical sciences · 2026Article
- Targeting the MAPK Pathway in Cancer.International journal of molecular sciences · 2025Review
- Fyn inhibition by TAE684: A synergistic strategy to suppress melanoma and reverse vemurafenib resistance.Cell death & disease · 2025Article
- Computational and pharmacophore-based study of Camellia sinensis phytochemicals targeting BRAF in melanoma.Scientific reports · 2025Article
- Squamous Cell Bladder Cancer: A Rare Histological Variant with a Demand for Modern Cancer Therapeutics.Cancers · 2025Review
- Phytochemicals FromJournal of skin cancer · 2025Article
- Article
- screenwerk: a modular tool for the design and analysis of drug combination screens.Bioinformatics (Oxford, England) · 2023Article
- SK119, a Novel Shikonin Derivative, Leads to Apoptosis in Melanoma Cell Lines and Exhibits Synergistic Effects with Vemurafenib and Cobimetinib.International journal of molecular sciences · 2022Article
- Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma.Cancer biology & therapy · 2021Review
- Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.British journal of cancer · 2021Article
- Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma.Translational oncology · 2020Article
- Article
- Induced cross-resistance of BRAFScientific reports · 2019Article
- Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs.Vaccines · 2018Article
- BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells.Oncotarget · 2018Article
- Methotrexate sensitizes drug-resistant metastatic melanoma cells toOncotarget · 2018Article
- Targeted agents and immunotherapies: optimizing outcomes in melanoma.Nature reviews. Clinical oncology · 2017Review
- Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Hormones & cancer · 2017Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
There have been significant advances in the treatment of malignant melanoma with the U.S. Food and Drug Administration approval of two drugs in 2011, the first drugs approved in 13 years. The developments of immune checkpoint modulation via cytotoxic T-lymphocyte antigen-4 blockade, with ipilimumab, and targeting of BRAF(V600), with vemurafenib or dabrafenib, as well as MEK, with trametinib, have been paradigm changing both for melanoma clinical practice and for oncology therapeutic development. These advancements, however, reveal new clinical questions regarding combinations and optimal sequencing of these agents in patients with BRAF mutant disease. We review the development of these agents, putative biomarkers, and resistance mechanisms relevant to their use, and possibilities for sequencing and combining these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.